EUCTR2015-002571-24-GB进行中（未招募）1 期
A Phase IIA Prospective, Single-Centre, Open Label Clinical Trial to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of Ambroxol in Patients with Parkinson Disease: Ambroxol in Disease Modification in Parkinson Disease - AiM-PD
Joint Research Office0 个研究点目标入组 24 人开始时间: 2019年2月12日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Male or female;
- •2. Age = 40 and = 80 years of age;
- •3. Confirmed diagnosis of Parkinson disease at any time; and Hoehn and Yahr criteria, confirmed staged between I – III, inclusive;
- •4. Able and willing to provide informed consent prior to any study related assessments and procedures at screening visit 1;
- •5. Capable of complying with all study procedures, including fasting lumbar puncture;
- •6. Willing to provide a blood sample for screening genomic for Parkinson Disease related DNA analysis and/or consent to Investigators obtaining and using participants previous DNA results if applicable;
- •7. Willing and able to self-administer oral ambroxol medication, from day 1 to 186 (at 60 mg TID (day 1-7), 120 mg TID (day 8-14), 180 mg TID (day 15-21), 300 mg TID (day 22-28) and 420 mg TID (day 29-186));
- •8. Able to travel to the participating study site;
- •9. A female participant is eligible to participate if she is of:
- •Non-childbearing potential defined as pre-menopausal females with a
- •documented tubal ligation or hysterectomy; or postmenopausal defined as 12
- •consecutive months of spontaneous amenorrhea, at least 6 weeks post-surgical
- •bilateral oophorectomy (with or without hysterectomy) or post tubal
- •ligation. In questionable cases, menopausal status will be confirmed by
- •demonstrating levels of follicle stimulating hormone (FSH) 25.8 – 134.8 IU/L
- •and oestradiol < 201 pmol/l at entry.
- •Women of child-bearing potential must use accepted contraceptive methods
- •(listed below), and must have a negative serum at screening visit 1 and
- •urine pregnancy tests at subsequent visits if applicable. An additional
- •pregnancy test will be performed, and results obtained, prior to
- •administration of the first dose of ambroxol.
- •Accepted contraception methods:
- •True abstinence: When this is in line with the preferred and usual lifestyle of the participant. [Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception).
- •Contraceptive Methods with a Failure Rate of < 1%:
- •Oral contraceptive, either combined or progestogen alone;
- •Injectable progestogen;
- •Implants of levonorgestrel;
- •Estrogenic vaginal ring;
- •Percutaneous contraceptive patches; -
- •Intrauterine device (IUD) or intrauterine system (IUS) that meets the <1% failure rate as stated in the product label;
- •Please note:
- •- All male and female participants of child bearing potential must agree with their partners to use double-barrier birth control or abstinence while participating in the study and for 2 weeks following the last dose of the study drug.
- •- Participants may continue to take PD medications including glutamate antagonists, anticholinergics, dopamine agonists, Levodopa (L-DOPA and decarboxylase (DDC) inhibitor), Monoamine oxidase B (MAO-B) inhibitors catechol-O-methyltransferase (COMT) inhibitors, beta blockers, selective serotonin uptake inhibitors (SSRIS), tricyclic antidepressants (TCAs) a
排除标准
- •Participants are excluded from participating in this study if 1 or more of the following criteria are met:
- •1. Current treatment with anticoagulants (e.g. warfarin) that might preclude safe completion of the lumbar puncture and in the opinion of the Investigator;
- •2. Current use of investigational medicinal product or participation in another interventional clinical trial or who have done so within 30 days prior to the first dose in the current study;
- •3. Exposure to more than three investigational medicinal products within 12 months prior to the first dose in the current study;
- •4. Confirmed dysphagia that would preclude self-administration of ambroxol up to 7 tablets TID for the duration of day 1 to day 186);
- •5. Significant known lower spinal malformations or other spinal abnormalities that would preclude lumbar puncture;
- •6. History of known sensitivity to the study medication,ambroxol or its excipients (lactose monohydrate, granulated microcrystalline cellulose, copovidone and magnesium stearate) in the opinion of the investigator that contraindicates their participation;
- •7. History of known rare hereditary disorders of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption;
- •8. Evidence or history of hypersensitivity to lidocaine or its derivatives;
- •9. History of drug abuse or alcoholism in the opinion of the Investigator that would preclude participation in the study;
- •10. Donation of blood (one unit or 350 ml) within three months prior to receiving the first dose of the study drug;
- •11. Pregnant or breastfeeding;
- •12. All participants of child bearing potential in the opinion of the Investigator that would preclude participation in the study and who do not agree to use double-barrier birth control or abstinence while participating in the study and for two weeks following the last dose of study drug;
- •13. Any clinically significant or unstable medical or surgical condition that in the opinion of the PI or PI-delegated clinician may put the participant at risk when participating in the study or may influence the results of the study or affect the participant’s ability to take part in the study, as determined by medical history, physical examinations, electrocardiogram (ECG), or laboratory tests. Such conditions may include:
- •a) Impaired renal function
- •b) Moderate/Severe hepatic impairment
- •c) A major cardiovascular event (e.g. myocardial infarction, acute coronary syndrome, decompensated congestive heart failure, pulmonary embolism, coronary revascularisation that occurred within 6 months prior to the screening visit.
研究者
相似试验
进行中（未招募）
不适用
A Phase II, single center open label, prospective trial to evaluate the efficacy and safety of mepolizumab for patients with refractory or relapsing Churg Strauss Syndrome - MEPOCHUSSChurg-Strauss-SyndromeMedDRA version: 9.1Level: LLTClassification code 10009164Term: Churg Strauss syndromeEUCTR2006-001791-20-DEniversity Hospital of Schleswig-Holstein (UKSH), Campus Lübeck
尚未招募
4 期
Clinical study to evaluate safety and efficacy of MyV3 Herbal Face care pack in patients to reduced Black spot, blemishes, pimples, scars and skin tan.CTRI/2024/05/067458MS Vee Herbal Care Pvt Ltd
尚未招募
4 期
A Single-Center, Prospective, Open Labeled, Phase IV Clinical Study to Evaluate Safety and Efficacy of MY V3 Immune Herbal Capsules in Healthy Participants.CTRI/2024/05/067457Sidhva Herbal and Foods Pondicherry
尚未招募
4 期
Study to Evaluate the Safety and Clinical Acceptability of the Carivalan® the Single Pill Combination (SPC) of Carvedilol/Ivabradine in Indian Patients with Chronic Heart Failure and/or Chronic Coronary SyndromeCTRI/2021/03/032399Serdia Pharmaceuticals India Private Limited
进行中（未招募）
1 期
A study of doxorubicin in combination with radiotherapy, temozolomide and valproic acid in pediatric and adolescent patients with newly diagnosed high grade glioma (glioblastoma multiforme (GBM) and diffuse intrinsic pontine glioma (DIPG)).EUCTR2015-002307-28-ITAZIENDA OSPEDALIERO-UNIVERSITARIA MEYER20